Ticker >

Shilpa Medicare share price

Shilpa Medicare Ltd.

NSE: SHILPAMED BSE: 530549 SECTOR: Pharmaceuticals & Drugs  49k   169   26

538.45
+5.40 (1.01%)
BSE: 12 Jun 04:01 PM

Price Summary

Today's High

₹ 543.9

Today's Low

₹ 532.5

52 Week High

₹ 561.15

52 Week Low

₹ 233.6

FinStar

Ownership Below Par
Stock price may face volatility due to ownership structure.
ValuationFair
The stock’s market price justifies its intrinsic value.
EfficiencyPoor
The company seems highly inefficient in case of asset management.
FinancialsWeak
Watch out! The company might not be able to sustain any adverse condition.
*It is just an analytical rating of the company and not an investment advice.

Company Essentials

Market Cap

5265.55 Cr.

Enterprise Value

5548.14 Cr.

No. of Shares

9.78 Cr.

P/E

195.47

P/B

1.99

Face Value

₹ 1

Div. Yield

0 %

Book Value (TTM)

₹  270.24

CASH

4.83 Cr.

DEBT

287.42 Cr.

Promoter Holding

50.01 %

EPS (TTM)

₹  2.75

Sales Growth

-30.61%

ROE

-2.37 %

ROCE

-1.61%

Profit Growth

-345.47 %

* Total debt includes long term borrowing, short term borrowing plus current maturities of long-term borrowing
* Ratios are based on latest Audited Financial Result.

Your Added Ratios

Please login to Add & View your own added ratios.

Login

Price Chart 1d 1w 1m 3m 6m 1Yr 3Yr 5Yr

 

Volume Chart 1d 1w 1m 3m 6m 1Yr 3Yr 5Yr

* Prices are based on daily market changes.
* The chart is based on the standalone earnings of the company. * Negative values and values more than 1000x in PE chart is considered 0.

Peer Comparison

View Full Peer Comparison
* The Peers list includes companies operating in the same industry and having comparable market cap.

 Group Companies

Track the companies of Group.

Ratios

Sales Growth

1 Year-30.61%
3 Year-32.52%
5 Year-19.69%

Profit Growth

1 Year-59.43%
3 Year-33.41%
5 Year-15.56%

ROE%

1 Year-2.37%
3 Year0.98%
5 Year5.27%

ROCE %

1 Year-1.61%
3 Year1.56%
5 Year6.07%

Debt/Equity

0.1357

Price to Cash Flow

2530.3

Interest Cover Ratio

-1.79835390946502

CFO/PAT (5 Yr. Avg.)

1.58819609146429

Share Holding Pattern

Promoter Pledging %

Date Promoter % Pledge %
Mar 2024 50.01 90.41
Dec 2023 50.01 90.41
Sep 2023 50.01 90.41
Jun 2023 50.01 12.9
Mar 2023 50.01 12.9
Investors List
* Figures given above are % of equity capital

 Strengths

  • Company has a healthy liquidity position with current ratio of 2.63022082742868.
  • The company has a good cash flow management; CFO/PAT stands at 1.58819609146429.

 Limitations

  • The company has shown a poor profit growth of -166.509178353462% for the Past 3 years.
  • The company has shown a poor revenue growth of -32.515341287495% for the Past 3 years.
  • Company has a poor ROE of 0.97810300441596% over the past 3 years.
  • Company has a poor ROCE of 1.55616268817415% over the past 3 years
  • Company has low Interest coverage ratio of -1.79835390946502.
  • Company has contingent liabilities of 510.0491 Cr.
  • The company is trading at a high EV/EBITDA of 46.8336.
  • Promoter pledging is high as 90.41%.

Quarterly Result (All Figures in Cr.)

PARTICULARS Mar 2023 Jun 2023 Sep 2023 Dec 2023 Mar 2024
Net Sales 66.5 83.74 74.61 63.98 87.45
Total Expenditure 80.27 68.4 67.32 67.28 80.49
Operating Profit -13.77 15.34 7.29 -3.3 6.96
Other Income 20.33 20.78 22.76 22.33 23.25
Interest 6.61 6.76 5.18 2.61 2.71
Depreciation 11.98 12.26 12.67 12.39 12.29
Exceptional Items -14.96 -6.34 -0.21 -0.12 -3.78
Profit Before Tax -26.99 10.76 12 3.91 11.43
Tax 1.94 2.86 5.39 1.21 1.69
Profit After Tax -28.93 7.9 6.6 2.7 9.74
Adjusted EPS (Rs) -3.33 0.91 0.76 0.31 1.12

Profit & Loss (All Figures in Cr. Adjusted EPS in Rs.)

PARTICULARS Mar 2019 Mar 2020 Mar 2021 Mar 2022 Mar 2023
Net Sales 663.88 805.97 257.05 356.95 247.7
Total Expenditure 476.96 568.18 228.58 345.93 302.88
Operating Profit 186.92 237.79 28.47 11.02 -55.17
Other Income 17.16 18.37 37.14 51.52 79.82
Interest 2.79 4.33 6.07 9.05 20.83
Depreciation 34.01 34.96 22.28 34.82 46.55
Exceptional Items 6.22 -4.54 52.95 8.81 -15.55
Profit Before Tax 173.5 212.34 90.21 27.49 -58.28
Tax 37.75 44.15 25.12 7.33 -8.79
Net Profit 124.11 193.72 184.39 140.99 57.19
Adjusted EPS (Rs.) 16.65 20.63 7.98 2.32 -5.7

Balance Sheet (All Figures are in Crores.)

Particulars Mar 2019 Mar 2020 Mar 2021 Mar 2022 Mar 2023
Equity and Liabilities
Share Capital 8.15 8.15 8.15 8.68 8.68
Total Reserves 1273.39 1445.27 1629.68 2056.99 2108.9
Borrowings 81.1 164.48 324.52 120.28 122.8
Other N/C liabilities 76.06 43.52 81.06 89.87 35.56
Current liabilities 229.59 359.86 473.98 161.65 241.41
Total Liabilities 1668.29 2021.28 2517.39 2896.12 2517.36
Assets
Net Block 510.84 517 640.9 565.78 608.93
Capital WIP 284.8 244.18 297.19 52.57 41.84
Intangible WIP 116.41 128.63 185.16 240.55 184.59
Investments 89.04 93.48 219.32 237.5 243.92
Loans & Advances 119.95 124.54 391.84 595.14 802.92
Other N/C Assets 26.83 5.76 3.1 895.15 0.2
Current Assets 520.42 907.69 779.9 309.44 634.95
Total Assets 1668.29 2021.28 2517.39 2896.12 2517.36
* Other Non-current Liabilities include Net deferred Liabilities

Cash Flows (All Figures are in Crores.)

PARTICULARS Mar 2019 Mar 2020 Mar 2021 Mar 2022 Mar 2023
Profit from operations 155.6 233.99 255.54 192.89 12.68
Adjustment 25.78 -5.39 -25.46 32.64 -35.56
Changes in Assets & Liabilities 18.23 -57.95 -117.1 -17.17 33.37
Tax Paid -35.45 -40.85 -43.34 -34.49 -8.41
Operating Cash Flow 164.16 129.79 69.63 173.87 2.08
Investing Cash Flow -214.71 -302.49 -238.13 -378.97 -94.8
Financing Cash Flow 8.17 170.1 255.58 97.23 87.68
Net Cash Flow -42.38 -2.59 87.08 -107.88 -5.04

Corporate Actions

Investors Details

PARTICULARS Mar 2023% Jun 2023% Sep 2023% Dec 2023% Mar 2024%
promoters 50.01 50.01 50.01 50.01 50.01
brijgopal innani 1.35 1.35 1.35 1.35 1.35
deepak kumar innani 3.15 3.15 3.15 3.15 3.15
dharmavati bhutada 7.15 7.15 7.15 7.15 7.15
kamalkishore innani 0.19 0.19 0.19 0.19 0.19
kantadevi inani 2.93 2.93 2.93 2.93 2.93
keerti innani 0.18 0.18 0.18 0.18 0.18
keshav bhutada 2.30 2.30 2.30 2.30 2.30
madhav vishnukant bhutada... 2.30 2.30 2.30 2.30 2.30
manjulatha innani 0.18 0.18 0.18 0.18 0.18
namrata bhutada 0.03 0.03 0.03 0.03 0.03
natamal innani 1.30 1.30 1.30 1.30 1.30
om prakash inani 3.30 3.30 3.30 3.30 3.30
priya innani 0.21 0.21 0.21 0.21 0.21
ramakant innani 1.73 1.73 1.73 1.73 1.73
ravi kumar innani 4.62 4.62 4.62 4.62 4.62
sagar innani 1.15 1.15 1.15 1.15 1.15
shakuntalabai innani 1.30 1.30 1.30 1.30 1.30
suraj kumar innani 4.59 4.59 4.59 4.59 4.59
taradevi innani 1.44 1.44 1.44 1.44 1.44
triveni inani 0.34 0.34 0.34 0.34 0.34
vishnukant chaturbhuj bhu... 7.33 7.33 7.33 7.33 7.33
vishnukanta inani 1.40 1.40 1.40 1.40 1.40
vishnukanth c bhutada - - 1.54 1.54 1.54
vishnukanth c bhutada (hu... 1.54 1.54 - - -
PARTICULARS Mar 2023% Jun 2023% Sep 2023% Dec 2023% Mar 2024%
investors 49.99 49.99 49.99 49.99 49.99
akash bhanshali 1.84 1.84 1.84 1.84 1.84
amal n parikh 1.95 1.95 1.03 1.03 1.03
cohesion mk best ideas su... - - 1.38 1.38 1.38
dovetail india fund class... - - 1.08 1.08 1.08
elm park fund limited - - - 1.38 1.38
icici prudential pharma h... - - - - 1.44
investor education and pr... - - 0.30 0.31 0.31
pivotal enterprises priva... 2.53 2.53 2.53 2.53 2.53
sapphire intrex limited - - 1.41 1.09 1.23
viral amal parikh - - 1.15 1.15 1.15
abhishek khaitan - - - 1.01 -
ta fii investors limited 3.48 3.48 3.48 3.48 -
india opportunities growt... - 1.08 - - -
investor education and pr... 0.33 0.30 - - -
malabar select fund 1.80 1.22 - - -
india opportunities growt... 1.08 - - - -
karthik sundar 1.14 - - - -
malabar india fund limite... 1.58 - - - -
think india opportunities... 2.02 - - - -

Annual Reports

Ratings & Research Reports

Company Presentations

Company News

Shilpa Medicare’s arm files first drug master file of Recombinant Human Albumin 20%4 Jun 2024, 5:06PM Shilpa Medicare - Quaterly Results23 May 2024, 4:15PM Shilpa Medicare - Quaterly Results23 May 2024, 4:15PM Shilpa Medicare - Quaterly Results23 May 2024, 4:15PM Shilpa Medicare’s marketing partner launches Pemetrexed injection18 Apr 2024, 12:11PM Shilpa Medicare informs about disclosure18 Apr 2024, 11:12AM AGES issues GMP certification to Shilpa Medicare’s Telangana unit16 Apr 2024, 6:13PM Shilpa Medicare raises Rs 499 crore through QIP15 Apr 2024, 11:27AM Shilpa Medicare gets nod to raise fund through QIP9 Apr 2024, 12:58PM USFDA concludes inspection at Shilpa Medicare’s Bio Analytical Laboratory 1 Mar 2024, 3:42PM Shilpa Medicare informs about disclosure 26 Feb 2024, 11:39AM Shilpa Medicare - Quaterly Results8 Feb 2024, 4:10PM Shilpa Medicare - Quaterly Results8 Feb 2024, 4:10PM Shilpa Medicare - Quaterly Results8 Feb 2024, 4:10PM EMA concludes inspection at Shilpa Medicare’s Bio Analytical Laboratory7 Feb 2024, 10:29AM Shilpa Medicare informs about disclosure 27 Jan 2024, 11:52AM Shilpa Medicare informs about disclosure19 Jan 2024, 3:36PM Shilpa Medicare’s Unit VI Bengaluru gets nod to manufacture Wafers13 Dec 2023, 9:49AM Shilpa Medicare to sell 4% stake in Sravathi17 Nov 2023, 9:59AM Shilpa Medicare - Quaterly Results10 Nov 2023, 2:57PM Shilpa Medicare - Quaterly Results10 Nov 2023, 2:57PM Shilpa Medicare acquires Pilnova Pharma in United States3 Nov 2023, 10:30AM TGA Australia concludes GMP inspection at Shilpa Medicare’s Telangana facility17 Oct 2023, 2:22PM Shilpa Medicare launches Naturally Derived Option for Treatment of Oral Mucositis in India 12 Oct 2023, 9:50AM Shilpa Medicare gets marketing authorization for Betahistine Dihydrochloride Orodispersible Films4 Sep 2023, 11:52AM Shilpa Medicare’s finished dosage form manufacturing facility clears GMP inspection by ANVISA, Brazil25 Aug 2023, 2:42PM Shilpa Medicare informs about disclosure19 Aug 2023, 2:11PM Shilpa Medicare - Quaterly Results10 Aug 2023, 2:18PM Shilpa Medicare - Quaterly Results10 Aug 2023, 2:18PM Shilpa Medicare - Quaterly Results10 Aug 2023, 2:18PM Shilpa Medicare informs about disclosure9 Aug 2023, 3:06PM Shilpa Medicare informs about disclosure 4 Jul 2023, 12:43PM Shilpa Medicare gets nod to manufacture, sale Lenvatinib Capsules of higher strengths30 Jun 2023, 11:40AM Shilpa Medicare’s arm gets marketing authorization permission for Adalimumab injection30 Jun 2023, 10:20AM Shilpa Medicare informs about conference call25 May 2023, 5:18PM Shilpa Medicare - Quaterly Results25 May 2023, 3:55PM Shilpa Medicare - Quaterly Results25 May 2023, 3:55PM Shilpa Medicare - Quaterly Results25 May 2023, 3:55PM Shilpa Medicare gets USFDA’s approval for New Drug Application for Pemetrexed Injection23 May 2023, 3:39PM Shilpa Medicare informs about disclosure26 Apr 2023, 2:37PM Shilpa Medicare gets USFDA’s final nod for Apremilast Tablets11 Apr 2023, 9:24AM Shilpa Medicare informs about credit rating28 Mar 2023, 4:45PM USFDA inspects Shilpa Medicare’s Analytical Services Division in Hyderabad11 Mar 2023, 4:52PM Shilpa Medicare informs about inspection11 Mar 2023, 12:01PM Shilpa Medicare - Quaterly Results14 Feb 2023, 4:24PM Shilpa Medicare - Quaterly Results14 Feb 2023, 4:24PM Shilpa Medicare - Quaterly Results14 Feb 2023, 4:24PM Shilpa Medicare introduces Capecitabine 1000 MG dispersible tablet17 Dec 2022, 4:27PM Shilpa Medicare’s Telangana facility gets Health Canada GMP approval1 Dec 2022, 4:11PM Shilpa Medicare submits related party transactions24 Nov 2022, 10:51AM

Shilpa Medicare Stock Price Analysis and Quick Research Report. Is Shilpa Medicare an attractive stock to invest in?

The Indian healthcare sector is expected to reach US$ 372 billion by 2022, driven by rising incomes, greater health awareness, lifestyle diseases and increasing access to insurance. Healthcare has become one of India’s largest sectors - both in terms of revenue and employment.

Healthcare comprises hospitals, medical devices, clinical trials, outsourcing, telemedicine, medical tourism, health insurance, and medical equipment. The structure of the healthcare delivery system in India consists of three broad segments: Primary care, Secondary care, and Tertiary care.

  • Primary care is the first point of contact between the population and the healthcare service providers. For example, Sub-center (SC), Primary Health Centre (PHC) and Community Health Centre (CHC) which is more relevant to rural areas (PHC’s).
  • Secondary care providers inpatient as well as outpatient medical services and includes simple surgical procedures. For example, District level & Mid-sized hospitals.
  • Tertiary care is the third level of the healthcare delivery system in the country. These hospitals are specialized consultative healthcare infrastructure. For example, Single specialty and Multi-specialty hospitals.

While healthcare services are offered by the public as well as private sectors, in urban as well as rural areas, generally people prefer private hospitals over public hospitals for treatment of diseases, illness, and sickness. So, let’s look into Shilpa Medicare and its performance over the period of time. Shilpa Medicare stock price today is Rs 537.75.

  • Operating cash flow ratio: It measures the adequacy of a company’s cash generated from operating activities to pay off short-term financial obligations. Shilpa Medicare cash from the operating activity was Rs 2.081 Cr.
     
  • Financial Strength: Health care organizations usually have high debt loads and low equity capital in their balance sheet. So, Debt to Equity ratio is important to analyze the company’s sustainability. Shilpa Medicare has a Debt to Equity ratio of 0.1357 , which is a strong indication for the company.
     
  • EPS growth: Investors should ensure the EPS figure is growing faster than revenue numbers because it indicates company management is increasing the efficiency with which it runs the company. In Shilpa Medicare , the EPS growth was -345.476467295354 % which is bad for the company.
     
  • Operating profit margin: It determines a company's potential earnings. It assesses how well-managed a company with respect to its basic overhead costs and other operating expenses, Shilpa Medicare has OPM of -22.2744668997424 % which is a bad sign for profitability.
     
  • ROE: Shilpa Medicare have a poor ROE of -2.36576722443531 %. ROE is an important financial parameter for hospitals & health care companies because they expand and grow rapidly. Therefore, ROE measures how efficiently a shareholder's fund is used for generating profits.
     
  • Share Price: - The current share price of Shilpa Medicare is Rs 537.75. One can use valuation calculators of ticker to know if Shilpa Medicare share price is undervalued or overvalued.
Last Updated on:
Brief about Shilpa Medicare

Shilpa Medicare Ltd. Financials: Check Share Price, Balance Sheet, Annual Report, Quarterly Results, Shareholding, Company Profile and News for Company Analysis

Shilpa Medicare Ltd. is a renowned pharmaceutical company that has made significant strides in the healthcare industry. With its headquarters located in the city of Raichur, Karnataka, the company has built a strong foundation in manufacturing and marketing a wide range of active pharmaceutical ingredients (APIs) and formulations. Shilpa Medicare Ltd. aims to provide affordable and accessible healthcare solutions to patients globally.

Shilpa Medicare Ltd. – Share Price

The share price of Shilpa Medicare Ltd. is a key indicator for potential investors. It reflects the market's perception of the company's performance and future prospects. Our pre-built screening tools enable investors to track the historical share price movements of Shilpa Medicare Ltd. and analyze the trends over time.

Shilpa Medicare Ltd. – Balance Sheet

The balance sheet of Shilpa Medicare Ltd. provides a snapshot of the company's financial position. It showcases the company's assets, liabilities, and shareholders' equity at a specific point in time. By studying the balance sheet, long-term investors can gain insights into the company's financial stability and growth potential. Our premium features allow investors to conduct fair value calculations using tools such as DCF analysis, BVPS analysis, earnings multiple approach, and DuPont analysis.

Shilpa Medicare Ltd. – Annual Report

The annual report of Shilpa Medicare Ltd. provides a comprehensive overview of the company's performance and achievements during a particular fiscal year. It includes detailed information about the company's business operations, financial statements, management discussions, and future strategies. Investors can download the annual reports from our website to gain deeper insights into Shilpa Medicare Ltd.'s activities.

Shilpa Medicare Ltd. – Dividend

Shilpa Medicare Ltd. acknowledges the value of its shareholders and has consistently rewarded them through dividends. Dividends are a portion of the company's profits distributed to shareholders as a return on their investments. The company's dividend policy, trends, and payout ratios can offer valuable information to long-term investors evaluating the attractiveness of Shilpa Medicare Ltd. as an investment opportunity.

Shilpa Medicare Ltd. – Quarterly Result

The quarterly results of Shilpa Medicare Ltd. provide a closer look at the company's financial performance and progress on a short-term basis. By analyzing the quarterly results, investors can assess the company's ability to generate revenue, manage costs, and sustain growth. Our website offers downloadable quarterly reports, allowing investors to stay updated on Shilpa Medicare Ltd.'s latest financial developments.

Shilpa Medicare Ltd. – Stock Price

Monitoring the stock price of Shilpa Medicare Ltd. is crucial for investors seeking stock analysis. Our pre-built screening tools provide access to real-time stock price data, historical price charts, and customizable technical indicators. With these tools, investors can track the movements of Shilpa Medicare Ltd.'s stock price and make informed decisions based on market trends and patterns.

Shilpa Medicare Ltd. – Price Chart

The price chart of Shilpa Medicare Ltd. enables investors to visually analyze the historical performance of the company's stock. By studying the price chart, long-term investors can identify trends, patterns, and potential buying or selling opportunities. Our website's pre-built screening tools incorporate advanced charting features to assist investors in conducting technical analysis effectively.

Shilpa Medicare Ltd. – News

Staying updated with the latest news about Shilpa Medicare Ltd. is essential for investors seeking stock analysis. Our website provides curated news articles that cover the company's recent developments, regulatory updates, partnerships, and product launches. Investors can access these news articles to gain insights into the factors that may influence Shilpa Medicare Ltd.'s stock performance.

Shilpa Medicare Ltd. – Concall Transcripts

Concall transcripts offer investors valuable information by providing a detailed record of the company's conference calls or earnings calls. These transcripts contain discussions between company management and analysts, providing insights into the company's financial results, future plans, and market outlook. Investors can download the concall transcripts from our website to gain a deeper understanding of Shilpa Medicare Ltd.'s operations and strategies.

Shilpa Medicare Ltd. – Investor Presentations

Investor presentations play a significant role in understanding a company's performance, strategies, and future growth prospects. Shilpa Medicare Ltd. provides downloadable investor presentations on our website to keep investors informed about the company's recent initiatives, financial highlights, and expansion plans. These presentations offer valuable insights to long-term investors looking for stock analysis.

Shilpa Medicare Ltd. – Promoters

Shilpa Medicare Ltd. is backed by a group of dedicated promoters who have been instrumental in shaping the company's growth and success. The promoters bring their expertise, vision, and strategic guidance to drive the company forward. Understanding the profile and background of the promoters can provide investors with valuable insights into the company's stability and growth potential.

Shilpa Medicare Ltd. – Shareholders

Shilpa Medicare Ltd. benefits from a diverse base of shareholders who have placed their trust in the company's potential for long-term growth. Monitoring the shareholder composition can provide investors with insights into the market sentiment towards Shilpa Medicare Ltd. and the level of conviction among institutional investors. Our pre-built screening tools enable investors to track changes in shareholder patterns and identify significant stakeholders.

At our website, we provide a range of tools and resources for long-term stock investors seeking comprehensive stock analysis of Shilpa Medicare Ltd. Our pre-built screening tools, downloadable annual reports, concall transcripts, investor presentations, and premium features for fair value calculations offer investors a wealth of information to make informed investment decisions.

Read More
X